March 18, 2019 by Dr. Juan Frias
American Liver Foundation, diabetes, Nonalcoholic fatty liver disease (NAFLD)
March 18, 2019, Pharmacy
The American Liver Foundation estimates that over 30% of the U.S. population has some degree of nonalcoholic fatty liver disease (NAFLD), the most common type of liver disease in the Western world. This can impact other facets of their overall health, because NAFLD has been linked to diabetes, obesity, insulin resistance and other metabolic risk
March 18, 2019 by Dave Chase
diabetes, insulin
March 18, 2019, Pharmacy
Last month, one furloughed government worker made national headlines by saying she had to ration her insulin because she couldn’t afford her co-pay, nor the ER bill, during the government shutdown. Recalling a day where her blood sugar was high, she admitted, “I just went to bed and hoped I’d wake up.” This is not
March 18, 2019 by Chain Drug Review
Feel More Like You, Walgreens
March 18, 2019, News
DEERFIELD, Ill. — Walgreens this month launched Feel More Like You, a first-of-its-kind pharmacy, health and beauty service available at no cost to help people living with cancer manage the medical and physical changes associated with cancer treatment. The national launch at more than 3,000 Walgreens stores follows a successful 100-store pilot program that began
March 18, 2019 by Chain Drug Review
AmerisourceBergen Foundation
March 18, 2019, News
VALLEY FORGE, Pa. — The AmerisourceBergen Foundation has committed $25,000 to support relief efforts in communities affected by the tornadoes that recently swept through the Southeast United States. The foundation has made a donation to the Community Foundation of East Alabama, a regional organization focused on identifying community needs, solving regional issues and improving the
March 18, 2019 by Chain Drug Review
CVS Health, Roshan Navagamuwa
March 18, 2019, News
WOONSOCKET, R.I. — CVS Health has named a new chief information officer tasked with integrating its information technology and data with IT systems used by Aetna, which the company acquired last year. Roshan Navagamuwa, who over the past year served as interim CIO, was named executive vice president and CIO of the combined health industry
March 18, 2019 by Joe Tarnowski
ECRM, wellness+
March 18, 2019, Opinion
Over the past few years we’ve all seen the impact of wellness on how customers shop. They are looking for cleaner and more functional ingredients and more organic foods, and even watching what HBC products they are putting on their face and skin. But we’re reaching a tipping point where wellness is no longer a
March 18, 2019 by Jeffrey Woldt
NACDS, NACDS RxImpact Day
March 18, 2019, Opinion
The National Association of Chain Drug Stores mobilized an impressive array of pharmacy advocates earlier this month to inform, educate and motivate members of Congress and other federal officials about the need to support policies that enable members of the profession to serve patients effectively. The 424 pharmacy proponents — including key executives from many
February 18, 2019 by Chain Drug Review
Alex Azar, NACDS
February 18, 2019, News
WASHINGTON — The National Association of Chain Drug Stores and the National Community Pharmacists Association (NCPA) have praised a bipartisan Senate letter to Health and Human Services Secretary Alex Azar. The letter thanked the secretary for concepts in the Centers for Medicare and Medicaid Services’ (CMS’) proposed rule, Modernizing Part D and Medicare Advantage to
February 18, 2019 by Chain Drug Review
2019 NACDS Regional Chain Conference, Mark Panzer, Rebecca Buble, Steve Anderson
February 18, 2019, News
PALM BEACH, Fla. — The National Association of Chain Drug Stores’ campaign-style approach to the issues crucial for pharmacy value and viability dominated this month’s opening session of the 2019 NACDS Regional Chain Conference. NACDS’ top-priority issue of direct and indirect remuneration (DIR) fee reform headlined the discussion of the association’s “Access Agenda” — which
February 18, 2019 by Laura Gurski
2019 retail trends, Accenture, Laura Gurski
February 18, 2019, Opinion
The industry continues to experience major shifts. And while the relentless pace of change can be daunting, the one thing any of us know for sure is that there’ll be more disruption ahead and standing still is not an option. Consumer expectations and exciting technology possibilities just keep expanding. Constant change is the new normal
February 18, 2019 by Chain Drug Review
Rite Aid
February 18, 2019, News
CAMP HILL, Pa. — Last month Rite Aid Corp. announced that its board of directors has approved a reverse stock split of the company’s common stock. The reverse stock split is intended to enable Rite Aid to regain full compliance with the New York Stock Exchange listing rules. The split is subject to stockholder approval.
February 18, 2019 by Jerry Cacciotti
health care costs
February 18, 2019, Opinion
Editor’s note: The fifth in a series of seven articles by A.T. Kearney on the trends that are radically transforming the health sector. America faces skyrocketing health care expenses. The Centers for Medicare and Medicaid Services (CMS) projects that national health spending will grow by 5.6% annually to 2025. The growth in health expenditures is
February 18, 2019 by Jeffrey Woldt
2019 NACDS Regional Chain Conference, DIR fees, Mark Panzer, Medicare Part D, NACDS, Steve Anderson
February 18, 2019, Opinion
The National Association of Chain Drug Stores was at the top of its game during the Regional Chain Conference in Palm Beach, Fla., earlier this month. Often overshadowed by the association’s larger events, this hidden gem provides attendees with an initial look at the objectives that NACDS and its members will pursue during the course
February 4, 2019 by Chain Drug Review
Hy-Vee, opioid abuse crisis
February 4, 2019, News
WEST DES MOINES, Iowa — To assist in combatting the national opioid epidemic, Hy-Vee Inc. has implemented a new controlled substance prescription policy. Since January 1, Hy-Vee pharmacies have not allowed a subsequent fill of a Schedule II controlled substance, or a refill of a Schedule III or Scheduled IV controlled substance more than 72